Taken together, balanced FAO and MRC activity and enhanced FAO and PGC-1α activity through AMPK activation may be promising therapeutic targets for ameliorating obesity-induced NAFLD [10,12]. This evidence concerns the gene CD200 and metabolic dysfunction-associated steatotic liver disease.